Jessica Marvel1, Tzy-Chyi Yu1, Robert Wood2, Victoria S Higgins2, Barry J Make3. 1. Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 2. Adelphi Real World, Adelphi Group, Bollington, Cheshire, United Kingdom. 3. Division of Pulmonary and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, Colorado.
Abstract
Background: Despite receiving treatment, patients with chronic obstructive pulmonary disease (COPD) often continue to experience symptoms that impact their health status. We determined the relationship between overall symptom burden and health status, and assessed the treatments patients were receiving. Methods: Data from 3 cross-sectional surveys of U.S. patients with COPD (2011-2013) were analyzed. Patients receiving inhaled COPD treatment for ≥3 months completed the COPD Assessment Test (CAT) symptom burden and respiratory health status measure, EuroQol 5-dimension (EQ-5D-3L) general health status questionnaire, and Jenkins Sleep Evaluation Questionnaire (JSEQ). CAT scores were used to identify high- (CAT ≥24) and low-symptom patients (CAT <24), who were matched using 1:1 propensity score matching with replacement. Match balance was assessed with standardized mean differences. EQ-5D-3L and JSEQ scores, and current treatment were compared between groups post-matching. Sensitivity was assessed with Rosenbaum bounds. Results: A total of 638 patients were included. Compared with low-symptom patients, high-symptom patients had worse health status and greater sleep disturbance by EQ-5D utility index (0.85 versus 0.71, respectively; p<0.0001) and JSEQ scores (3.73 versus 7.35, respectively; p<0.0001). High-symptom patients were prescribed single-maintenance bronchodilators ± inhaled corticosteroids (46.0%), triple therapy (40.5%), and short-acting therapy only (8.2%). Results were robust and insensitive to unobserved confounders. Conclusions: Increased COPD symptom burden is associated with worse general health status in patients receiving COPD treatment. High-symptom patients frequently received single inhaled medication. The results suggest that health care providers should monitor and tailor therapy, based on level of symptom burden to improve symptom control and health status.
Background: Despite receiving treatment, patients with chronic obstructive pulmonary disease (COPD) often continue to experience symptoms that impact their health status. We determined the relationship between overall symptom burden and health status, and assessed the treatments patients were receiving. Methods: Data from 3 cross-sectional surveys of U.S. patients with COPD (2011-2013) were analyzed. Patients receiving inhaled COPD treatment for ≥3 months completed the COPD Assessment Test (CAT) symptom burden and respiratory health status measure, EuroQol 5-dimension (EQ-5D-3L) general health status questionnaire, and Jenkins Sleep Evaluation Questionnaire (JSEQ). CAT scores were used to identify high- (CAT ≥24) and low-symptom patients (CAT <24), who were matched using 1:1 propensity score matching with replacement. Match balance was assessed with standardized mean differences. EQ-5D-3L and JSEQ scores, and current treatment were compared between groups post-matching. Sensitivity was assessed with Rosenbaum bounds. Results: A total of 638 patients were included. Compared with low-symptom patients, high-symptom patients had worse health status and greater sleep disturbance by EQ-5D utility index (0.85 versus 0.71, respectively; p<0.0001) and JSEQ scores (3.73 versus 7.35, respectively; p<0.0001). High-symptom patients were prescribed single-maintenance bronchodilators ± inhaled corticosteroids (46.0%), triple therapy (40.5%), and short-acting therapy only (8.2%). Results were robust and insensitive to unobserved confounders. Conclusions: Increased COPD symptom burden is associated with worse general health status in patients receiving COPD treatment. High-symptom patients frequently received single inhaled medication. The results suggest that health care providers should monitor and tailor therapy, based on level of symptom burden to improve symptom control and health status.
Entities:
Keywords:
GOLD strategy; copd; health status; standard of care; symptom burden
Authors: Xavier Perez; Juan P Wisnivesky; Linda Lurslurchachai; Lawrence C Kleinman; Ian M Kronish Journal: Respir Med Date: 2011-10-13 Impact factor: 3.415
Authors: T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha Journal: Am J Respir Crit Care Med Date: 1998-05 Impact factor: 21.405
Authors: Sarah Wilke; Paul W Jones; H Müllerova; Jørgen Vestbo; Ruth Tal-Singer; Frits M E Franssen; Alvar Agusti; Per Bakke; Peter M Calverley; Harvey O Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; William MacNee; Stephen I Rennard; Julie C Yates; Emiel F M Wouters; Martijn A Spruit Journal: Thorax Date: 2015-03-17 Impact factor: 9.139
Authors: Nurdan Kokturk; Mehmet Polatli; I Kivilcim Oguzulgen; Sarfraz Saleemi; Mohammed Al Ghobain; Javed Khan; Adam Doble; Luqman Tariq; Fayaz Aziz; Abdelkader El Hasnaoui Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-04-27